Tokyo, May 8 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061476) titled 'A single arm phase III trial to evaluate the efficacy of Alectinib 300 mg BID as adjuvant therapy in resected ALK positive non small cell lung cancer in a Japanese population' on May 7.
Study Type:
Interventional
Study Design:
Basic Design - Single arm
Randomization - Non-randomized
Blinding - Open -no one is blinded
Control - Historical
Primary Sponsor:
Institute - Public Health Research Foundation
Condition:
Condition - ALK positive non small cell lung cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - The aim of the study is to evaluate the efficacy and ...